Aripiprazole Tablet
Product Images NDC 0904-7367

16 FDA label images from Major Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 0904-7367). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Aripiprazole Tablets 1)

1 (Aripiprazole Tablets 1)
Chemical structure of Aripiprazole, showing its molecular framework including a dichlorophenyl group, a piperazine ring, and a quinolinone moiety, connected by an ether-linked chain.*
FDA Label Image

1 (Aripiprazole Tablets 2)

1 (Aripiprazole Tablets 2)
A pharmacokinetic chart showing the effect of various drugs on aripiprazole. It illustrates fold changes and 90% confidence intervals for aripiprazole's AUC and Cmax values when co-administered with CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and other drugs. The x-axis represents change relative to reference without interacting drugs.*
FDA Label Image

1 (Aripiprazole Tablets 3)

1 (Aripiprazole Tablets 3)
A pharmacokinetic chart titled "Effect of Other Drugs on Aripiprazole" showing dehydro-aripiprazole fold change with 90% confidence intervals. The chart compares the impact of various inhibitors, inducers, and other drugs on Aripiprazole AUC and Cmax relative to a reference without interacting drugs, with values ranging from about 0.5 to 3.0 fold change.*
FDA Label Image

1 (Aripiprazole Tablets 4)

1 (Aripiprazole Tablets 4)
A forest plot chart illustrating the effect of Aripiprazole on the pharmacokinetics of various drugs, including CYP2D6 substrates (dextromethorphan), CYP2C9 and CYP2C19 substrates (warfarin), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis represents change relative to reference values without interacting drugs, with fold change and 90% confidence intervals shown for each drug. The plot assesses changes in drug exposure parameters such as AUC and Cmax.*
FDA Label Image

1 (Aripiprazole Tablets 5)

1 (Aripiprazole Tablets 5)
A pharmacokinetic chart illustrating the fold change and 90% confidence interval in aripiprazole exposure (AUC and Cmax) across special populations, including comparisons for CYP2D6 poor versus extensive metabolizers, gender, age groups (18-64 vs. >65 years), levels of hepatic impairment (mild, moderate, severe vs. normal), and severe renal impairment. The x-axis represents change relative to reference values.*
FDA Label Image

1 (Aripiprazole Tablets 6)

1 (Aripiprazole Tablets 6)
A pharmacokinetic chart showing the fold change and 90% confidence interval of Dehydro-Aripiprazole relative to reference across various factors: CYP2D6 metabolic status, gender, age groups, hepatic impairment levels, and severe renal impairment. The x-axis measures change relative to reference, and the y-axis lists the factors with corresponding AUC and Cmax values.*
FDA Label Image

1 (Aripiprazole Tablets 7)

1 (Aripiprazole Tablets 7)
A Kaplan-Meier curve comparing the proportion of subjects with relapse over 182 days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk is listed below the graph for both groups.*
FDA Label Image

1 (Aripiprazole Tablets 8)

1 (Aripiprazole Tablets 8)
A Kaplan-Meier survival curve chart comparing the proportion with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The chart includes numbers of subjects at risk at different time points for both groups.*
FDA Label Image

1 (Aripiprazole Tablets 9)

1 (Aripiprazole Tablets 9)
A line graph comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis represents days, with numbers of subjects at risk below, and the y-axis shows the proportion with relapse. The graph includes a legend differentiating Aripiprazole (solid line) and placebo (dashed line).*
FDA Label Image

1 (Aripiprazole Tablets 10)

1 (Aripiprazole Tablets 10)
Line chart showing change in YGTSS Total TIC Score from baseline over 8 weeks of treatment, comparing Aripiprazole low dose, Aripiprazole high dose, and placebo. The y-axis represents the least-squares mean change in YGTSS Total TIC Score, and the x-axis represents weeks of treatment. The chart illustrates a greater reduction in score with both doses of Aripiprazole compared to placebo over time.*
FDA Label Image

2mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 05)

2mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 05)
Aripiprazole 2 mg oral tablets USP in Unit Dose packaging by Major Pharmaceuticals. The label displays NDC 0904-7366-04 and indicates a package size of 30 tablets (3 x 10). The label includes directions for pharmacists to dispense with a medication guide and storage instructions, along with a barcode and the manufacturer’s information.*
FDA Label Image

5mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 04)

5mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 04)
Aripiprazole 5 mg Tablets, USP unit dose packaging label from Major Pharmaceuticals. The label shows an NDC of 0904-7367-06 and indicates the package contains 50 tablets (5 strips of 10). Additional information includes storage instructions, medication guide dispensing note for pharmacists, and manufacturer details in Indianapolis, IN.*
FDA Label Image

10mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 03)

10mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 03)
Label for Aripiprazole 10 mg oral tablets manufactured by Major Pharmaceuticals. The label indicates this is a unit dose package containing 50 tablets (5 strips of 10). It includes directions to dispense with a medication guide, storage instructions, warning to keep out of reach of children, and distributor information for Major Pharmaceuticals in Indianapolis, IN.*
FDA Label Image

15mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 02)

15mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 02)
Unit dose packaging label for Aripiprazole Tablets USP 15 mg by Major Pharmaceuticals. The label indicates a package size of 30 tablets (3 blister cards of 10 tablets each). It includes storage instructions and medication guide dispensing information, with the product labeled as prescription only.*
FDA Label Image

20mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 01)

20mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 01)
Aripiprazole 20 mg Unit Dose tablets label from Major Pharmaceuticals. The label indicates 30 tablets (3 x 10), specifies prescription use only, and includes storage instructions to keep between 20° to 25°C with permissible excursions. It notes the package is not child resistant and is intended for institutional use only. The label also lists NDC 0904-7370-04 and the manufacturer location in Indianapolis, IN.*
FDA Label Image

30mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 00)

30mg Carton Label (C125d854 8bb2 4467 83b4 C8a0e0f893c8 00)
Aripiprazole 30 mg oral tablets, USP, unit dose packaging containing 30 tablets (3 strips of 10). Label includes NDC 0904-7371-04, pharmacist dispensing instructions, storage conditions, and warnings. Packaged and distributed by Major Pharmaceuticals, Indianapolis, IN, USA.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.